New Orleans to host world's experts in lymphoma this weekend

This weekend the Ernest N. Morial Convention Center in New Orleans will host many of the world's experts on blood disorders like lymphomas and leukemias as the American Society of Hematology (ASH), publishers of the esteemed journal Blood, holds its 51st Annual Meeting from December 5-8 2009.

Dubbing itself "the premier hematology meeting in the world", organizers are expecting over 20,000 attendees.

The annual meeting is typically a time to highlight emerging treatment modalities, diagnostic trends, clinical trial results and new ideas in the field of blood disorders, and this year is no different, although among myriad events they will be recognizing the 150th anniversary of Charles Darwin's On the Origin of Species with an evolutionary biologist looking at leukemia from a Darwinian perspective.

Read about more of the events this weekend here.

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap